BioCentury | Feb 15, 2020
Translation in Brief

COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

...in patient samples by triggering collateral cleavage of a reporter RNA (see “SHERLOCK: Leveraging CRISPR, SynBio...
BioCentury | Dec 1, 2016
Clinical News

ErepoXen: Additional Ph II data

...from the first and second cohorts of the trial (see BioCentury, Aug. 3, 2015 ). SynBio...
...rights to co-develop Xenetic’s ErepoXen in Russia, while Serum Institute has co-development rights in India. SynBio LLC...
...Safety and hemoglobin levels Status: Additional Phase II data Milestone: NA Alicia Parker ErepoXen Serum Institute of India Ltd. SynBio LLC Xenetic...
BioCentury | Aug 3, 2015
Clinical News

ErepoXen: Phase II data

...hemoglobin therapeutic range. This year, Xenetic expects data from the third cohort of the trial. SynBio...
...rights to co-develop Xenetic’s ErepoXen in Russia, while Serum Institute has co-development rights in India. SynBio LLC...
BioCentury | Nov 4, 2013
Clinical News

ErepoXen: Phase II started

...up to 72 adults with CKD who are not receiving dialysis or erythropoiesis-stimulating agents (ESAs). SynBio...
...rights to co-develop Xenetic's ErepoXen in Russia, while Serum Institute has co-development rights in India. SynBio LLC...
BioCentury | Aug 12, 2013
Clinical News

ErepoXen: Phase II started

...up to 72 adults with CKD who are not receiving dialysis or erythropoiesis-stimulating agents (ESAs). SynBio...
...rights to co-develop Xenetic's ErepoXen in Russia, while Serum Institute has co-development rights in India. SynBio LLC...
BioCentury | May 20, 2013
Clinical News

ErepoXen: Phase III started

...Xenetic said partner SynBio began a 24-month, open-label, Russian Phase III trial comparing ErepoXen vs. Aranesp...
...patients with stage 3 or 4 CKD. Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) markets Aranesp. SynBio...
...rights to co-develop Xenetic's ErepoXen in Russia, while Serum Institute has co-development rights in India. SynBio LLC...
BioCentury | Jan 30, 2012
Clinical News

OncoHist: Phase I/II started

...Xenetic said SynBio began a dose-escalation, Russian Phase I/II trial to evaluate 500, 750, 1,125 and...
...recombinant human histone H1.3 technology, which Xenetic gained through its acquisition of SymbioTec GmbH . SynBio...
...of Independent States (CIS) to OncoHist (see BioCentury, Dec. 5, 2011 & Jan. 23, 2012). SynBio LLC...
BioCentury | Dec 5, 2011
Company News

SynBio, Rusnano hematology, endocrine/metabolic, infectious news

...invested RUB900 million ($28.7 million) in biobetters company SynBio. The investment represents a 41.4% stake. SynBio...
...provide RUB1.3 billion ($46.7 million), while the other founders will co-invest the remaining RUB1.9 billion. SynBio...
...for liver disease based on the Gemacell platform. SynBio owns a 50.2% stake in Xenetic. SynBio LLC...
BioCentury | Dec 5, 2011
Financial News

SynBio completes venture financing

SynBio LLC , Moscow, Russia Business: Hepatic, Cardiovascular, Endocrine/Metabolic Date completed: 11/30/11 Type: Venture financing Raised: RUB900 million ($28.7 million) Investor: Rusnano WIR Staff Cardiovascular Hepatic Infectious...
BioCentury | Dec 5, 2011
Finance

Highlights of weekly biotech stock moves

...£12.2 million ($19.1 million) through the sale of 110.8 million shares in a placing to SynBio LLC...
...to Xenetic's close of 9.25p on Aug. 3, the day before the offering was announced. SynBio...
Items per page:
1 - 10 of 18
BioCentury | Feb 15, 2020
Translation in Brief

COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

...in patient samples by triggering collateral cleavage of a reporter RNA (see “SHERLOCK: Leveraging CRISPR, SynBio...
BioCentury | Dec 1, 2016
Clinical News

ErepoXen: Additional Ph II data

...from the first and second cohorts of the trial (see BioCentury, Aug. 3, 2015 ). SynBio...
...rights to co-develop Xenetic’s ErepoXen in Russia, while Serum Institute has co-development rights in India. SynBio LLC...
...Safety and hemoglobin levels Status: Additional Phase II data Milestone: NA Alicia Parker ErepoXen Serum Institute of India Ltd. SynBio LLC Xenetic...
BioCentury | Aug 3, 2015
Clinical News

ErepoXen: Phase II data

...hemoglobin therapeutic range. This year, Xenetic expects data from the third cohort of the trial. SynBio...
...rights to co-develop Xenetic’s ErepoXen in Russia, while Serum Institute has co-development rights in India. SynBio LLC...
BioCentury | Nov 4, 2013
Clinical News

ErepoXen: Phase II started

...up to 72 adults with CKD who are not receiving dialysis or erythropoiesis-stimulating agents (ESAs). SynBio...
...rights to co-develop Xenetic's ErepoXen in Russia, while Serum Institute has co-development rights in India. SynBio LLC...
BioCentury | Aug 12, 2013
Clinical News

ErepoXen: Phase II started

...up to 72 adults with CKD who are not receiving dialysis or erythropoiesis-stimulating agents (ESAs). SynBio...
...rights to co-develop Xenetic's ErepoXen in Russia, while Serum Institute has co-development rights in India. SynBio LLC...
BioCentury | May 20, 2013
Clinical News

ErepoXen: Phase III started

...Xenetic said partner SynBio began a 24-month, open-label, Russian Phase III trial comparing ErepoXen vs. Aranesp...
...patients with stage 3 or 4 CKD. Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) markets Aranesp. SynBio...
...rights to co-develop Xenetic's ErepoXen in Russia, while Serum Institute has co-development rights in India. SynBio LLC...
BioCentury | Jan 30, 2012
Clinical News

OncoHist: Phase I/II started

...Xenetic said SynBio began a dose-escalation, Russian Phase I/II trial to evaluate 500, 750, 1,125 and...
...recombinant human histone H1.3 technology, which Xenetic gained through its acquisition of SymbioTec GmbH . SynBio...
...of Independent States (CIS) to OncoHist (see BioCentury, Dec. 5, 2011 & Jan. 23, 2012). SynBio LLC...
BioCentury | Dec 5, 2011
Company News

SynBio, Rusnano hematology, endocrine/metabolic, infectious news

...invested RUB900 million ($28.7 million) in biobetters company SynBio. The investment represents a 41.4% stake. SynBio...
...provide RUB1.3 billion ($46.7 million), while the other founders will co-invest the remaining RUB1.9 billion. SynBio...
...for liver disease based on the Gemacell platform. SynBio owns a 50.2% stake in Xenetic. SynBio LLC...
BioCentury | Dec 5, 2011
Financial News

SynBio completes venture financing

SynBio LLC , Moscow, Russia Business: Hepatic, Cardiovascular, Endocrine/Metabolic Date completed: 11/30/11 Type: Venture financing Raised: RUB900 million ($28.7 million) Investor: Rusnano WIR Staff Cardiovascular Hepatic Infectious...
BioCentury | Dec 5, 2011
Finance

Highlights of weekly biotech stock moves

...£12.2 million ($19.1 million) through the sale of 110.8 million shares in a placing to SynBio LLC...
...to Xenetic's close of 9.25p on Aug. 3, the day before the offering was announced. SynBio...
Items per page:
1 - 10 of 18